FDA Proposes Collaborative Approach for Pediatric Rare Disease Research

Clinical Trials Advisor
For more efficient development of treatments for pediatric rare diseases, sponsors can implement controlled, multi-arm, multi-company clinical trials, according to a new draft guidance that the FDA says could help eliminate the need for certain studies.

To View This Article:


Subscribe To Clinical Trials Advisor